These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10087954)

  • 21. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S41-4. PubMed ID: 8769700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
    Reiter A; Marley SB; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon MY; Goldman JM; Cross NC
    Br J Haematol; 1998 Sep; 102(5):1271-8. PubMed ID: 9753056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
    Talwar R; Choudhry VP; Jobanputra V; Kucheria K
    Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
    Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The detection of Philadelphia chromosome negative metaphases in long-term bone marrow cultures of the peripheral blood from patients with chronic myeloid leukemia predicts response to interferon-alpha 2a.
    Gronthos S; To LB; Moore S; Suttle JM; Juttner CA
    Leukemia; 1992 Dec; 6(12):1246-9. PubMed ID: 1453769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
    Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
    Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment].
    Casado LF; Picó M; Gómez C; Ferro MT; Fernández-Rañada JM; Steegmann JL
    Med Clin (Barc); 1997 Sep; 109(7):251-5. PubMed ID: 9333689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
    Müller-Tidow C; Kiehl M; Sindermann JR; Probst M; Banger N; Zühlsdorf M; Chou TC; Berdel WE; Serve H; Koch OM
    Int J Oncol; 2003 Jul; 23(1):151-8. PubMed ID: 12792788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interferon-alpha in the treatment of chronic myeloid leukemia].
    Guilhot F
    Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
    [No Abstract]   [Full Text] [Related]  

  • 37. [Interferon alfa-2b treatment of adult patients during early chronic phase of Ph1-positive chronic myeloid leukemia (initial report on a cooperative study, protocol CML-MIG-97)].
    Khoroshko ND; Turkina AG; Zakharova AV; Kobzev IuN; Domracheva EV; Tikhonova LIu; Semenova EA; Zhuravlev VS; Sokolova MA; Kuznetsov SV
    Ter Arkh; 1999; 71(7):42-7. PubMed ID: 10481867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
    El Eit RM; Iskandarani AN; Saliba JL; Jabbour MN; Mahfouz RA; Bitar NM; Ayoubi HR; Zaatari GS; Mahon FX; De Thé HB; Bazarbachi AA; Nasr RR
    Int J Cancer; 2014 Feb; 134(4):988-96. PubMed ID: 23934954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia.
    Iwama H; Ohyashiki K; Ohyashiki JH; Hayashi S; Kawakubo K; Shay JW; Toyama K
    Cancer; 1997 Apr; 79(8):1552-60. PubMed ID: 9118038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of chronic myelogenous leukemia.
    Talpaz M; Kantarjian H; McCredie K; Trujillo J; Keating M; Gutterman JU
    Cancer; 1987 Feb; 59(3 Suppl):664-7. PubMed ID: 10822467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.